Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. - Université de Lille Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Future Oncology Année : 2024

Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.

J. S. Abramson
  • Fonction : Auteur
S. R. Solomon
  • Fonction : Auteur
J. Arnason
  • Fonction : Auteur
P. B. Johnston
  • Fonction : Auteur
B. Glass
  • Fonction : Auteur
V. Bachanova
  • Fonction : Auteur
S. Ibrahimi
  • Fonction : Auteur
S. Mielke
  • Fonction : Auteur
P. Mutsaers
  • Fonction : Auteur
F. Hernandez-Ilizaliturri
  • Fonction : Auteur
K. Izutsu
  • Fonction : Auteur
M. Lunning
  • Fonction : Auteur
A. Crotta
  • Fonction : Auteur
S. Montheard
  • Fonction : Auteur
A. Previtali
  • Fonction : Auteur
K. Ogasawara
  • Fonction : Auteur
M. Kamdar
  • Fonction : Auteur

Résumé

People diagnosed with a disease called large B-cell lymphoma (LBCL) may experience return, or early relapse, of their disease within the first year after receiving and responding to their first (first-line) treatment regimen. Others may have primary refractory disease, meaning that the disease either did not respond to first-line treatment at all or only responded for a very brief period. Second (second-line) treatment includes immunotherapy followed by high-dose chemotherapy and ASCT, which has the potential to cure LBCL. However, if the disease does not respond to immunotherapy, people cannot receive ASCT, and less than 30% of people are cured. Therefore, new second-line treatment options are required, such as CAR T cell therapy, which uses a person's own genetically engineered lymphocytes, also called T cells, to fight their lymphoma. In this article, we summarize the key results of the phase 3 TRANSFORM clinical study that tested if liso-cel, a CAR T cell treatment, can safely and effectively be used as a second-line treatment for people with early relapsed or primary refractory (relapsed/refractory) LBCL. A total of 184 adults with relapsed/refractory LBCL who were able to receive ASCT were randomly treated with either liso-cel or standard of care (SOC) as second-line treatment. SOC included immunochemotherapy followed by high-dose chemotherapy and ASCT.
Fichier principal
Vignette du fichier
Plain language summary of the TRANSFORM study primary analysis results liso-cell as a second treatment regimen for large B-cell lymphoma following fa.pdf (5.92 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04603093 , version 1 (06-06-2024)

Identifiants

Citer

J. S. Abramson, S. R. Solomon, J. Arnason, P. B. Johnston, B. Glass, et al.. Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.. Future Oncology, 2024, Future Oncology, pp.1-11. ⟨10.2217/fon-2023-0898⟩. ⟨hal-04603093⟩

Collections

UNIV-LILLE
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More